• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cibus Appoints Co-Founder Rory Riggs, as Chief Executive Officer

    10/7/21 9:00:00 AM ET
    $FGEN
    $ITCI
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FGEN alert in real time by email

    Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company.

    "Since our founding, Rory has been an important strategic partner in the success of Cibus and we are pleased that he is deepening his involvement in the company's growth as CEO," said Dr. Beetham. "With the recent progress toward a European approval of Cibus' proprietary precision gene-editing technology, as well as other recent Cibus commercial announcements, this management shift is an important step in scaling Cibus to address the enormous opportunities that exist in the global agriculture solutions market."

    "Cibus' Rapid Trait Development System™ technology is set to play a leading role in the global drive to make farming more efficient and sustainable. The tremendous technological breakthroughs in gene editing by our scientists and others, have placed agriculture at a major point of inflection in the use of environmentally sound biological solutions to address both farming sustainability and agriculture's impact on climate change," said Mr. Riggs.

    "Cibus' focus is productivity improvements in the major row crops: canola, rice, soybean, wheat, and corn. These crops are grown annually on billions of acres of land. Addressing the use of chemicals and the impact of climate change on these major global crops is critical to achieving virtually every sustainable development and climate goal. I am excited to work more closely with the team at Cibus in this enormous opportunity to make Cibus a global leader in the transformation of agriculture."

    Mr. Riggs has an extensive record of executive leadership and innovation in the healthcare and biotechnology fields. He is a co-founder, former Chairman and director of Royalty Pharma (NASDAQ:RPRX), the largest acquirer of pharmaceutical royalties and leading funder of innovation in the life sciences. In addition, he has co-founded and served on the board of several important biotechnology companies including Sugen (NASDAQ:SUGN) and Fibrogen (NASDAQ:FGEN).

    Previously, Mr. Riggs served as President and director of Biomatrix, Inc. (NYSE:BXM) from 1996 until its sale to Sanofi/Genzyme. During his tenure, he led the development and global commercial launch of an important new category for the treatment of osteoarthritis: viscosupplementation; and the leading product in the category: Synvisc®. Mr. Riggs also served as CEO of RF&P Corp., an investment company owned by the Virginia Retirement System until its sale to Lazard. He is a Director of Intra-cellular Therapies, Inc (NASDAQ:ITCI); Stage Zero Life Sciences (OTC:SZLSF), and a co-founder and Partner of Scientia Ventures LLC, a leading venture investor in Cibus. He was formerly a Managing Director at PaineWebber, Inc.

    Mr. Riggs is also a pioneer in the field of Systems Economics and the inventor of a new information system called FIS® (Functional Information System) for the functional mapping of systems data in biology and economics. This technology is covered by several patents of which one is with Dr. Beetham and Greg Gocal, PhD, Cibus' Chief Scientific Officer. FIS is currently the basis for two investment and research analytics companies: Syntax LLC and Locus Analytics LLC.

    "The addition of Rory to our executive team is a major step in accomplishing our goal of redefining and reshaping the agricultural crop protection business," said Dr. Gocal, co-founder, Chief Scientific Officer and Executive Vice President at Cibus. "The continued technological breakthroughs in genomics and gene editing have created a generational moment in one of the most exciting scientific periods of our lifetime and we look forward to making significant contributions to improve farming through biology."

    Mr. Riggs received his BA from Middlebury College and his MBA from Columbia University's Graduate School of Business.

    About Cibus

    Cibus is a leading agricultural biotechnology company that uses precision gene editing to breed plants with new genetic traits that make them healthier and better able to thrive in their changing environments. Cibus' traits improve farming productivity by increasing crop yields and reducing inputs such as fungicides, herbicides, pesticides, and fertilizers. Cibus' trait products are important drivers of farming sustainability and the reduction of agriculture's carbon footprint. For more information, please visit www.cibus.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005383/en/

    Get the next $FGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FGEN
    $ITCI
    $RPRX

    CompanyDatePrice TargetRatingAnalyst
    Royalty Pharma plc
    $RPRX
    9/30/2025$42.00Buy
    Goldman
    Royalty Pharma plc
    $RPRX
    5/16/2025$51.00Overweight
    Morgan Stanley
    Intra-Cellular Therapies Inc.
    $ITCI
    2/24/2025$140.00 → $132.00Outperform → Neutral
    Mizuho
    Intra-Cellular Therapies Inc.
    $ITCI
    1/31/2025$119.00 → $132.00Buy → Hold
    Canaccord Genuity
    Intra-Cellular Therapies Inc.
    $ITCI
    9/6/2024$68.00 → $92.00Neutral → Overweight
    Piper Sandler
    Royalty Pharma plc
    $RPRX
    6/3/2024$28.00Buy → Neutral
    UBS
    Intra-Cellular Therapies Inc.
    $ITCI
    1/3/2024$83.00Outperform
    Robert W. Baird
    Intra-Cellular Therapies Inc.
    $ITCI
    12/11/2023$75.00Outperform
    TD Cowen
    More analyst ratings

    $FGEN
    $ITCI
    $RPRX
    SEC Filings

    View All

    FibroGen Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - FIBROGEN INC (0000921299) (Filer)

    1/7/26 4:15:12 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Royalty Pharma plc

    8-K - Royalty Pharma plc (0001802768) (Filer)

    12/22/25 4:13:15 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Royalty Pharma plc

    8-K - Royalty Pharma plc (0001802768) (Filer)

    12/22/25 11:37:20 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Wettig Thane bought $33,750 worth of shares (3,700 units at $9.12), increasing direct ownership by 17% to 24,939 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    11/17/25 4:42:52 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schoeneck James A bought $119,485 worth of shares (23,567 units at $5.07) (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    7/2/25 4:33:27 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane bought $50,663 worth of shares (145,000 units at $0.35), increasing direct ownership by 36% to 543,329 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    3/25/25 9:00:05 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

    Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royaltiesRoyalty Pharma maintained industry leadership with announced transactions of $4.7 billion Multiple potential value-creating milestones expected across development-stage portfolio in 2026, including pivotal data readouts for daraxonrasib, litifilimab and pelacarsen NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board, will discuss these updates on January 13, 2026 as part of a webcast presentation

    1/12/26 7:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to acce

    1/11/26 5:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (NASDAQ:RPRX), today announced a funding agreement of up to $500 million to accel

    1/11/26 5:00:00 PM ET
    $RPRX
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Research & Investments Urist Marshall sold $815,634 worth of Class A Ordinary Shares (20,000 units at $40.78) (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    1/13/26 5:37:44 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Mcgivern Arthur Richard

    3 - Royalty Pharma plc (0001802768) (Issuer)

    1/6/26 4:20:31 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CFO Coyne Terrance P. sold $2,673,041 worth of Class A Ordinary Shares (69,582 units at $38.42) (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    1/6/26 4:18:43 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Royalty Pharma with a new price target

    Goldman initiated coverage of Royalty Pharma with a rating of Buy and set a new price target of $42.00

    9/30/25 8:57:42 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Royalty Pharma with a new price target

    Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

    5/16/25 8:05:49 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intra-Cellular Therapies downgraded by Mizuho with a new price target

    Mizuho downgraded Intra-Cellular Therapies from Outperform to Neutral and set a new price target of $132.00 from $140.00 previously

    2/24/25 7:10:56 AM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

    NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. "I am delighted to welcome Ted to the key role of Lead Independent Director," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. "Ted has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization's (BIO)

    9/29/25 8:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors

    Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma's commitment to enhanced corporate governance following acquisition of its external manager NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global pr

    7/17/25 8:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

    SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. "Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board," said James Schoeneck, chairman of the board of directors of FibroGen. "His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael's deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers." "FibroGen has differentiated potential first-in-class assets and

    6/9/25 4:02:00 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/14/24 4:52:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/12/24 4:01:23 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by FibroGen Inc

    SC 13G/A - FIBROGEN INC (0000921299) (Subject)

    11/12/24 2:33:26 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FGEN
    $ITCI
    $RPRX
    Financials

    Live finance-specific insights

    View All

    Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to acce

    1/11/26 5:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (NASDAQ:RPRX), today announced a funding agreement of up to $500 million to accel

    1/11/26 5:00:00 PM ET
    $RPRX
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Announces Dividend Increase

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company's quarterly dividend over the previous quarter's dividend. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non

    1/9/26 8:30:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care